Scarica l'app Stockscreener
0.3111
7.55%
-0.0254
Dopo l'orario di chiusura:
.32
0.0089
+2.86%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$0.3365
Aprire:
$0.3112
Volume 24 ore:
3.13M
Relative Volume:
1.60
Capitalizzazione di mercato:
$76.70M
Reddito:
$9.10M
Utile/perdita netta:
$-82.47M
Rapporto P/E:
-0.5364
EPS:
-0.58
Flusso di cassa netto:
$-72.32M
1 W Prestazione:
-23.56%
1M Prestazione:
-33.78%
6M Prestazione:
-61.55%
1 anno Prestazione:
-71.19%
Intervallo 1D:
$0.2899
$0.341
Intervallo di 1 settimana:
$0.2899
$0.41
Portata 52W:
$0.2899
$1.11
Vaxart Inc Stock (VXRT) Company Profile
Nome
Vaxart Inc
Settore
Industria
Telefono
(650) 550-3500
Indirizzo
170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA
Confronta VXRT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VXRT
Vaxart Inc
|
0.3111 | 76.70M | 9.10M | -82.47M | -72.32M | -0.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Vaxart Inc Stock (VXRT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-15 | Iniziato | Oppenheimer | Outperform |
| 2021-12-29 | Ripresa | Jefferies | Buy |
| 2021-11-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-06-29 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-06-24 | Iniziato | Jefferies | Buy |
| 2021-06-11 | Iniziato | Piper Sandler | Overweight |
| 2020-08-12 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-13 | Iniziato | B. Riley FBR | Buy |
Mostra tutto
Vaxart Inc Borsa (VXRT) Ultime notizie
VXRT stock touches 52-week low at $0.31 amid market challenges - Investing.com India
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
RFK Jr. pauses $240 million contract for new ‘oral COVID vaccine’ - Todayville
VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates - MSN
Vaxart reports inducement grants under Nasdaq listing rule - TipRanks
Vaxart Stock Hits 52-Week Low at $0.45 Amid Market Challenges - Investing.com
Vaxart Stock Hits 52-Week Low at $0.45 Amid Market Challenges By Investing.com - Investing.com South Africa
Vaxart Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vaxart's Major Talent Investment: 659,500 Share Awards and Key Executive Hire Signals Growth - Stock Titan
B. Riley Cuts Price Target on Vaxart to $2 From $2.50, Keeps Buy Rating - MarketScreener
Vaxart, Inc. (NASDAQ:VXRT) Q4 2024 Earnings Call Transcript - Insider Monkey
Vaxart Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Oral - Vaxart Inc.
Sudden Trump administration order prompts Bay Area company to lay off staff - SFGATE
Bay Area biotech company lays off staff over sudden Trump admin order - SFGATE
Vaxart Inc to offer up to $50 mln of common stock -March 21, 2025 at 04:42 pm EDT - MarketScreener
RFK Jr. paused this Peninsula company's half-billion-dollar vaccine contract, then it cut jobs - The Business Journals
Vaxart Inc Reports Q4 EPS of -$0.12, Missing Estimates; Revenue at $19.5 Million, Below Expectations - GuruFocus
Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments ... - Yahoo Finance
Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments Amid Challenges - GuruFocus.com
Vaxart Reports 2024 Financial Results and Vaccine Progress - TipRanks
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Vaxart, Inc. Investors of Important Deadline in Securities Class Action – VXRT - Business Wire
Earnings call transcript: Vaxart Q4 2024 misses EPS but beats revenue - Investing.com India
Vaxart Inc. (VXRT) reports earnings - Quartz
Vaxart Provides Business Update And Reports Full Year 2024 Financial Results -March 20, 2025 at 04:49 pm EDT - MarketScreener
Vaxart, Inc. SEC 10-K Report - TradingView
Vaxart Provides Business Update and Reports Full Year 2024 Financial Results - GlobeNewswire
Vaxart Quadruples Revenue to $28.7M as New Norovirus Vaccine Trial Launches - Stock Titan
FDA Mid-Month ID Food Recall Safety Updates - ContagionLive
Pipeline - Vaxart Inc.
Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20 - GlobeNewswire
Vaxart, Inc. to Host Conference Call for Business Update and Financial Results on March 20, 2025 - Nasdaq
Vaxart's Crucial 2024 Financial Update: Management to Reveal Full-Year Performance - Stock Titan
ElectroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Vaxart starts early-stage study for its pill-based vaccine for norovirus -March 11, 2025 at 08:57 am EDT - Marketscreener.com
Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate - GlobeNewswire
First-Ever Norovirus Pill Vaccine Enters Clinical Trials: Vaxart's Game-Changing Approach - StockTitan
Financial Survey: Quince Therapeutics (NASDAQ:QNCX) & Vaxart (NASDAQ:VXRT) - Defense World
Our Science - Vaxart Inc.
Vaxart's Oral Norovirus Vaccine: Key Study Findings and Future Plans - Contagionlive.com
Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults - The Manila Times
Vaxart (VXRT) Projected to Post Quarterly Earnings on Thursday - Defense World
Vaxart reports promising norovirus vaccine trial results By Investing.com - Investing.com Canada
Vaxart reports promising norovirus vaccine trial results - Investing.com
Vaxart Inc Azioni (VXRT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):